Inactive Instrument

News Galena Biopharma Inc Nasdaq

Equities

US3632565046

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation	Jul. 08	MT
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia	Jul. 08	AQ
SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia	Jul. 08	CI
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia	Jun. 24	AQ
SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia	Jun. 24	CI
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia	Jun. 17	AQ
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia	Jun. 17	CI
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML	Jun. 10	AQ
SELLAS Life Sciences Group, Inc. Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML	Jun. 10	CI
Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	May. 18	CI
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update	May. 14	AQ
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	May. 01	AQ
SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	May. 01	CI
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	Apr. 29	AQ
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	Apr. 29	CI
North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update	Mar. 28	AQ
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Transcript : SELLAS Life Sciences Group, Inc. - Special Call	Mar. 26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Galena Biopharma Inc Nasdaq

Equities

US3632565046

Summary

Filters